Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRC105 and Bevacizumab in Bevacizumab-Refractory Glioblastoma
NCT01564914Phase 2Completed
- Sponsor
- TRACON Pharmaceuticals, Inc.
- Start
- May 2012
- Primary completion
- Jun 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of carotuximab in glioblastoma multiforme (GBM), sponsored by TRACON Pharmaceuticals, Inc.. Started May 2012; status: completed.
02
Drugs
carotuximab
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT01564914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01564914.